AMPH
Amphastar Pharmaceuticals, Inc.
AMPH's fundamentals are mixed, but it looks cheap: trading at 13x earnings, below its usual 19x. Analysts expect earnings growth, though they disagree widely on how much.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
AMPH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Strong | |
| Stable |
AMPH's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
AMPH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 8.9x | $28.87 | — |
| Cheap | 12x | $25.21 | -13% |
| Current | 13x | $28.87 | — |
| Fair | 19x | $40.83 | +41% |
| Expensive | 89x | $196 | +578% |
Historical ranges are pointers, not guarantees.
AMPH's PE is in its cheap range at 13x. If earnings grow as analysts expect, today's price would be 8.9x next year's earnings.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
AMPH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| Low |
AMPH has the edge over HIMS on the outlook, with more favorable earnings expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
AMPH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.26 | +49% |
| Q3 2026 | $2.19 | -3.1% |
| Q2 2026 | $1.69 | -37% |
| Q1 2026 | $1.66 | -40% |
| Q4 2025 | $2.03 | -34% |
| Q3 2025 | $2.26 | -25% |
| Q2 2025 | $2.67 | -15% |
| Q1 2025 | $2.76 | -5.2% |
| Q4 2024 | $3.06 | +18% |
AMPH has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
AMPH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $207.6M | +8.2% |
| Q2 2026 | $183.9M | +5.4% |
| Q1 2026 | $171.2M | +0.4% |
| Q4 2025 | $183.1M | -1.8% |
| Q3 2025 | $191.8M | +0.3% |
| Q2 2025 | $174.4M | -4.4% |
| Q1 2025 | $170.5M | -0.8% |
| Q4 2024 | $186.5M | +4.7% |
AMPH's revenue grew through 2024 and has held roughly level since: $208M last quarter, up 8.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 24% | +11 points |
| Q2 2026 | 22% | -2.6 points |
| Q1 2026 | 8% | -14 points |
| Q4 2025 | 19% | -4.8 points |
| Q3 2025 | 13% | -17 points |
| Q2 2025 | 24% | -6.1 points |
| Q1 2025 | 22% | -6.1 points |
| Q4 2024 | 24% | -6.1 points |
AMPH has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over AMPH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
AMPH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $33.4M | -29% |
| Q2 2026 | $42.7M | +71% |
| Q1 2026 | $38.3M | +57% |
| Q4 2025 | $24.6M | +48% |
| Q3 2025 | $47.2M | +2.3% |
| Q2 2025 | $25M | -60% |
| Q1 2025 | $24.4M | -48% |
| Q4 2024 | $16.6M | +15% |
AMPH generated $139M in free cash flow over the past year, up 23% from the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over AMPH on cash flow, with more consistent year-over-year improvement.
AMPH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.9% | -848K shares |
| 1 year | -9% | -4.3M shares |
| 3 years | -20% | -10.5M shares |
| 5 years | -13% | -6.6M shares |
| Available history | -7.4% | -3.5M shares |
AMPH has the edge over HIMS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $438,000 |
| Q2 2026 | $45.2M |
| Q1 2026 | $29.5M |
| Q4 2025 | $20.5M |
| Q3 2025 | $4.9M |
| Q2 2025 | $39.2M |
| Q1 2025 | $11M |
| Q4 2024 | $42M |
AMPH spent $96M buying back its own shares over the past year, down 1.5% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has 234M diluted shares, down 6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
AMPH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.1x | Moderate |
| Q2 2026 | 2.3x | Moderate |
| Q1 2026 | 2.5x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.9x | Healthy |
| Q2 2025 | 1.8x | Healthy |
| Q1 2025 | 1.8x | Healthy |
| Q4 2024 | 1.9x | Healthy |
AMPH's net debt is about 2.1 years of its operating earnings (EBITDA), up from 1.9 years a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
AMPH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 67.2 | Neutral |
| Stochastic | 86.2 | Overbought |
AMPH's weekly RSI is 67 (neutral) and its Stochastic is 86 (overbought).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
AMPH PE vs Healthcare Sector
| Metric | AMPH | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 49% below |
| PE % | 25 | 29 | 4 pts below |
AMPH is trading at 13x earnings, a 49% discount to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
AMPH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $26.8 | 7.8% above |
| 20 week MA | $23.4 | 24% above |
| 50 week MA | $23.0 | 26% above |
| 100 week MA | $25.3 | 14% above |
| 200 week MA | $35.8 | 19% below |
AMPH has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
AMPH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $19.2 | $19.1 | -0.3% |
| 2021 | $19.1 | $22.6 | +18% |
| 2022 | $22.6 | $28.7 | +27% |
| 2023 | $28.7 | $61.9 | +116% |
| 2024 | $61.9 | $37.8 | -39% |
| 2025 | $37.8 | $27.1 | -28% |
| 2026 YTD | $27.1 | $28.9 | +6.5% |
AMPH has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.